Showing results (231-240 of 255) with videos related to

Sort By:
Pageof 26
Cancer Science|September 17, 2022
Gankyrin and TIGAR cooperatively accelerate glucose metabolism toward the PPP and TCA cycle in hepatocellular carcinomaChun Yang, Xiao-Wen Cui, Zhi-Wen Ding, et al.
Science Translational Medicine|September 24, 2020
PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinomaTian-Yi Jiang, Yu-Fei Pan, Zheng-Hua Wan, et al.
Cell Death & Disease|April 29, 2024
Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinomaXin Li, Yu-Fei Pan, Yi-Bin Chen, et al.
Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica|March 12, 2026
[Research progress in neuroprotective effects of Bacopa monnieri active components and derivatives in neurological disorders]Lyu-Yuan Liang, Jia-Lei Cao, Zi-Lin Zhao, et al.
Lipids in Health and Disease|January 23, 2024
Residual risk of cardiovascular complications in statin-using patients with type 2 diabetes: the Taiwan Diabetes Registry StudyChin-Sung Kuo, Nai-Rong Kuo, Yun-Kai Yeh, et al.
The International Journal of Biochemistry & Cell Biology|April 15, 2014
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistanceHui Zhang, Rishil J Kathawala, Yi-Jun Wang, et al.
Medicine|May 18, 2019
Efficacy of traditional Chinese medicine for chronic gastritis: A meta-analysis of randomized controlled trialsZi-Xing Yan, Yun-Kai Dai, Teng Ma, et al.
Molecular Cancer Therapeutics|March 8, 2017
The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and TumorsHui Zhang, Atish Patel, Yi-Jun Wang, et al.
Injury Epidemiology|October 2, 2025
Fine particulate matter exposure and risk of scooter collisions among older adultsHsuan-Min Kao, Yi-Ching Lo, Chung-Yi Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating MutationBenjamin P Brown, Yun-Kai Zhang, David Westover, et al.
Pageof 26